Alkermes Re-initiates FY20 Adj. EPS Outlook, In Line With Estimates - Quick Facts

(RTTNews) - While reporting financial results for the second quarter on Wednesday, biopharmaceutical company Alkermes plc (ALKS) re-initiated its earnings and revenue guidance for the full-year 2020. This guidance reflects the anticipated net impacts of the COVID-19 pandemic on Alkermes' operating and financial results.

For fiscal 2020, the company now projects a loss in a range of $0.91 to $1.10 per share and adjusted earnings in the range of $0.00 to $0.19 per share on total revenues between $965 million and $1.01 billion.

On average, analysts polled by Thomson Reuters expect the company to report a loss of $0.01 per share on revenues of $983.04 million for the year. Analysts' estimates typically exclude special items.

The company projects VIVITROL net sales between $270 million and $300 million as well as ARISTADA net sales between $220 million and $235 million.

Alkermes said it anticipates that the negative impact of COVID-19 on VIVITROL net sales will be partially offset by a decrease in operating expenses, notably within R&D.

The company had previously withdrawn its 2020 financial expectations in late April, due to uncertainties regarding the impact of the COVID-19 pandemic on its business.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos


Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Learn More